GlassScriptPhysician profile
Valeria D Richards
NPI 1962828251
$3,502.68
in general payments reported to CMS, 2019-2025
23 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $795 · 2023: $1,167 · 2024: $1,186 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,602.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $779.57 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $749.09 | 2021-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $276.67 | 2022-2025 | |
| Genzyme Corporation | $239.18 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $222.09 | 2022-2025 | Entyvio |
| Ironwood Pharmaceuticals, INC | $140.05 | 2021-2024 | Linzess |
| Pfizer INC. | $134.49 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $126.62 | 2023-2024 | Dupixent |
| Janssen Biotech, INC. | $124.93 | 2021-2024 | Tremfya, Stelara |
| Ardelyx, INC. | $123.26 | 2022-2025 | Ibsrela |
| Celgene Corporation | $109.46 | 2021-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $91.71 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $79.83 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $75.20 | 2022-2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $37.70 | 2024 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $35.30 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $33.37 | 2024-2025 | Givlaari |
| Ferring Pharmaceuticals INC. | $27.71 | 2022-2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $26.36 | 2024 | Iqirvo |
| Aimmune Therapeutics, INC. | $24.56 | 2024 | |
| Alexion Pharmaceuticals, INC. | $16.63 | 2022 | |
| Evoke Pharma, INC. | $15.06 | 2025 | |
| Redhill Biopharma INC. | $13.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valeria Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.